Evidence map›Paper›PMID 26273198›Full record

ReviewDrug design, development and therapy2015

The role of aflibercept in the management of diabetic macular edema.

Andrew A Chang, Thomas Hong, Shaun Y Ewe, Bobak Bahrami, Geoffrey K Broadhead

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Drug design, development and therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Observational
  5. Article
  6. Retinal and choroidal angiogenesis: a review of new targets.International journal of retina and vitreous · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Andrew A ChangSydney Institute of Vision Science, University of Sydney, Sydney, NSW, Australia ; Sydney Retina Clinic and Day Surgery, University of Sydney, Sydney, NSW, Australia ; Save Sight Institute, University of Sydney, Sydney, NSW, Australia.
Thomas HongSydney Institute of Vision Science, University of Sydney, Sydney, NSW, Australia ; Sydney Retina Clinic and Day Surgery, University of Sydney, Sydney, NSW, Australia.
Shaun Y EweSydney Institute of Vision Science, University of Sydney, Sydney, NSW, Australia ; Sydney Retina Clinic and Day Surgery, University of Sydney, Sydney, NSW, Australia.
Bobak BahramiSydney Institute of Vision Science, University of Sydney, Sydney, NSW, Australia ; Sydney Retina Clinic and Day Surgery, University of Sydney, Sydney, NSW, Australia.
Geoffrey K BroadheadSydney Institute of Vision Science, University of Sydney, Sydney, NSW, Australia ; Sydney Retina Clinic and Day Surgery, University of Sydney, Sydney, NSW, Australia ; Save Sight Institute, University of Sydney, Sydney, NSW, Australia.
Retina Clinic · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetic macular edema (DME) represents one of the leading causes of visual impairment in working-age adults. Although there are several proven treatments available for this condition, pharmacotherapy through the use of intravitreal antivascular endothelial growth factor agents has revolutionized the management of DME over the past decade with superior outcomes compared to laser therapy. This review summarizes the pathophysiology and available treatment options for the management of DME, with an emphasis on the efficacy and safety profile of a single particular intravitreal antivascular endothelial growth factor agent, aflibercept.

Indexed as

AdultAnimalsDiabetic RetinopathyHumansIntravitreal InjectionsMacular EdemaReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsVascular Endothelial Growth Factor AafliberceptReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsVascular Endothelial Growth Factor Aafliberceptdiabetic macular edema

Identifiers

PMID26273198
PMCPMC4532215
OpenAlexW1847066967

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.